Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)



Status:Archived
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2009
End Date:June 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging (MRI)


This will be an international, multi-center, post-marketing surveillance study in patients
with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI.
Omniscan will be administered intravenously at the medical discretion of the prescribing
physician.



We found this trial at
1
site
GE Healthcare
Princeton, New Jersey 08540
?
mi
from
Princeton, NJ
Click here to add this to my saved trials